ALZAMEND NEURO
Alzamend Neuro is an innovative biotechnology company that develops and commercializes drugs, treatments, and cures for Alzheimer's disease. The company also focused on the facilitation of bringing technologies to market which help with the treatment, prevention, or cure of Alzheimer’s. They providing hope through the commercialization of existing patented intellectual property while simultaneously funding future treatments through advanced research and development. Alzamend Neuro was founded in 2016 and is headquartered in Newport Beach, CA, USA.
ALZAMEND NEURO
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2016-01-01
Address:
Newport Beach, California, United States
Country:
United States
Website Url:
http://www.alzamend.com
Status:
Active
Contact:
(844) 722-6333
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Cytodiagnostics
Cytodiagnostics is a biotechnology company and developing nanotechnology derived products and services for life science research.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
OvaGene Oncology
OvaGene is an in-revenue growth company that develops and commercializes Molecular Diagnostics for women.
Precise Bio
Precise Bio is a regenerative medicine company that develops and commercializes 4D bio-fabricated functional tissues and organs.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.alzamend.com
- Host name: ecngx318.inmotionhosting.com
- IP address: 70.39.144.94
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Alzamend Neuro"
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro® , Inc., (“Alzamend® ”), a Delaware corporation with its headquarters in Atlanta, Georgia, is a clinical-stage, biopharmaceutical company. At Alzamend, we are committed to …See details»
Corporate Overview – Alzamend Neuro
Alzamend Neuro® , Inc., (“Alzamend® ”), a Delaware corporation with its headquarters in Atlanta, Georgia, is a clinical-stage, biopharmaceutical company. At Alzamend, we are committed to …See details»
Alzamend Neuro - Crunchbase Company Profile & Funding
Alzamend Neuro is an innovative biotechnology company that develops and commercializes drugs, treatments, and cures for Alzheimer's disease.See details»
Management – Alzamend Neuro
20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governanceSee details»
Alzamend Neuro Partners with Massachusetts General Hospital for …
ATLANTA, August 19, 2024--Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of …See details»
Alzamend Neuro announces initiation date of Phase II trial of AL001
Mar 25, 2025 In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend aims to explore the unique properties of AL001 and its effects on …See details»
Alzamend Neuro - businessabc
Feb 25, 2025 Alzamend Neuro was founded in 2006 by Dr. Brian Krauth, who is a professor of neurology at the University of Michigan. With a decade of experience in clinical research, Dr. …See details»
Alzamend Neuro Announces Initiation Date of Phase II
Mar 25, 2025 Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission …See details»
Company Information :: Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro® , Inc., (“Alzamend® ”), a Delaware corporation with its headquarters in Atlanta, Georgia, is a clinical-stage, biopharmaceutical company. At Alzamend, we are committed to …See details»
Alzamend Neuro Announces Initiation Date of Phase II Clinical …
Mar 11, 2025 About Alzamend Neuro Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD …See details»
Alzamend Neuro Announces Initiation Date of Phase II Clinical …
Mar 25, 2025 In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend aims to explore the unique properties of AL001 and its effects on …See details»
Alzamend Neuro Partners with Massachusetts General Hospital for …
Aug 12, 2024 Alzamend and Mass General have contracted with Dr. Ovidiu Andronesi MD, PhD, to be the principal investigator on the study. Dr. Andronesi is an Associate Professor of …See details»
Alzamend Neuro Partners with Massachusetts General
Aug 12, 2024 Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission …See details»
Alzamend Neuro Announces Closing of Initial Public Offering and …
Jun 17, 2021 Tampa, FL – (Business Newswire – June 17, 2021) – Alzamend Neuro, Inc. (“ Alzamend ”), a preclinical stage biopharmaceutical company focused on developing novel …See details»
Phase 2 Clinical Trial of AL001 for Major Depressive Disorder ...
Mar 19, 2025 Alzamend announced a late 2025 initiation for the phase 2 clinical study of AL001, a novel lithium-delivery system for the treatment of patients with major depressive disorder.See details»
Alzamend Neuro Announces Completion of a Novel Head Coil by …
Feb 19, 2025 In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend intends to undertake pioneering clinical trials, with a goal to assess …See details»
Alzamend Neuro Receives FDA “Study May Proceed” Notification …
Nov 20, 2023 According to the World Health Organization, approximately 280 million people (3.8% of the world’s population) in the world suffer from MDD. About Alzamend Neuro …See details»
Featured – Alzamend Neuro
Tampa, FL – (Business Newswire – June 17, 2021) – Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the …See details»
Alzamend Neuro Announces Full Data Set From Phase 1 First-in …
Mar 28, 2022 ATLANTA-- (BUSINESS WIRE)-- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel …See details»
Alzamend Neuro Partners with Massachusetts General Hospital for …
Aug 19, 2024 Alzamend and Mass General have contracted with Dr. Ovidiu Andronesi, MD, PhD, to be the principal investigator on the study. Dr. Andronesi is an Associate Professor of …See details»